Drug permeation and metabolism in Mycobacterium tuberculosis: prioritising local exposure as essential criterion in new TB drug development

Por Tanner, Lloyd, Denti, Paolo, Wiesner, Lubbe, Warner, Digby F.
Publicado no IUBMB Life (2018)

Add-On Aliskiren Elicits Stronger Renoprotection Than High-Dose Valsartan in Type 2 Diabetic KKAy Mice That Do Not Respond to Low-Dose Valsartan

Por Lei, Bai, Nakano, Daisuke, Fan, Yu-Yan, Kitada, Kento, Hitomi, Hirofumi, Kobori, Hiroyuki, Mori, Hirohito, Masaki, Tsutomu, Nishiyama, Akira
Publicado em 2012

Development of PPAR-agonist GW0742 as antidiabetic drug: study in animals

Por Niu, Ho-Shan, Ku, Po-Ming, Niu, Chiang-Shan, Cheng, Juei-Tang, Lee, Kung-Shing
Publicado no Drug Des Devel Ther (2015)

Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery

Por Dou, Huanyu, Destache, Christopher J., Morehead, Justin R., Mosley, R. Lee, Boska, Michael D., Kingsley, Jeffrey, Gorantla, Santhi, Poluektova, Larisa, Nelson, Jay A., Chaubal, Mahesh, Werling, Jane, Kipp, James, Rabinow, Barrett E., Gendelman, Howard E.
Publicado em 2006

Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges?

Por Smith, R.J
Publicado em 2005

On the importance of targeting parasite stem cells in anti-echinococcosis drug development

Por Brehm, Klaus, Koziol, Uriel
Publicado no Parasite (2014)

Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature

Por Kavanagh, David, McGlasson, Sarah, Jury, Alexa, Williams, Jac, Scolding, Neil, Bellamy, Chris, Gunther, Claudia, Ritchie, Diane, Gale, Daniel P., Kanwar, Yashpal S., Challis, Rachel, Buist, Holly, Overell, James, Weller, Belinda, Flossmann, Oliver, Blunden, Mark, Meyer, Eric P., Krucker, Thomas, Evans, Stephen J. W., Campbell, Iain L., Jackson, Andrew P., Chandran, Siddharthan, Hunt, David P. J.
Publicado no Blood (2016)

Development and evaluation of fixed dose bi therapy sublingual tablets for treatment stress hypertension and anxiety

Por El-Nabarawi, Mohamed A., Tayel, Saadia A., Soliman, Nadia A., Abo Enin, Hadel A.
Publicado em 2013

All-trans retinoic acid can antagonize osteoblastogenesis induced by different BMPs irrespective of their dimerization types and dose-efficiencies

Por Liu Y, Ma X, Guo J, Lin Z, Zhou M, Bi W, Liu J, Wang J, Lu H, Wu G
Publicado em 2018-10-01

Repurposing the anticancer drug cisplatin with the aim of developing novel Pseudomonas aeruginosa infection control agents

Por Yuan, Mingjun, Chua, Song Lin, Liu, Yang, Drautz-Moses, Daniela I, Yam, Joey Kuok Hoong, Aung, Thet Tun, Beuerman, Roger W, Salido, May Margarette Santillan, Schuster, Stephan C, Tan, Choon-Hong, Givskov, Michael, Yang, Liang, Nielsen, Thomas E
Publicado no Beilstein J Org Chem (2018)

ASSESSMENT OF EFFECTS OF DRUGS AVERSECT FORTE AND AVERSECT COMBI ON EMBRYONIC DEVELOPMENT OF THE RAT

Por M. V. Semenova, E. I. Koveshnikova
Publicado em 2016-12-01

Discovery and Development of the Anti-Human Immunodeficiency Virus Drug, Emtricitabine (Emtriva, FTC)

Por Liotta, Dennis C., Painter, George R.
Publicado no Acc Chem Res (2016)

An FDA-Approved Drug Screen for Compounds Influencing Craniofacial Skeletal Development and Craniosynostosis

Por Seda, Marian, Geerlings, Maartje, Lim, Peggy, Jeyabalan-Srikaran, Jeshmi, Cichon, Ann-Christin, Scambler, Peter J., Beales, Philip L., Hernandez-Hernandez, Victor, Stoker, Andrew W., Jenkins, Dagan
Publicado no Mol Syndromol (2019)

Re-orienting anti-malarial drug development to better serve pregnant women

Por Myriam El Gaaloul, Belen Tornesi, Flynn Lebus, David Reddy, Wiweka Kaszubska
Publicado em 2022-04-01

The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes

Por Seelig, Eleonora, Howlett, James, Porter, Linsey, Truman, Lucy, Heywood, James, Kennet, Jane, Arbon, Emma L., Anselmiova, Katerina, Walker, Neil M., Atkar, Ravinder, Pekalski, Marcin L., Rytina, Ed, Evans, Mark, Wicker, Linda S., Todd, John A., Mander, Adrian P., Bond, Simon, Waldron-Lynch, Frank
Publicado no JCI Insight (2018)

Development of an Interleukin-1β Vaccine in Patients with Type 2 Diabetes

Por Cavelti-Weder, Claudia, Timper, Katharina, Seelig, Eleonora, Keller, Cornelia, Osranek, Martin, Lässing, Ute, Spohn, Gunther, Maurer, Patrik, Müller, Philipp, Jennings, Gary T, Willers, Joerg, Saudan, Philippe, Donath, Marc Y, Bachmann, Martin F
Publicado no Mol Ther (2016)

Formulation and Quality Determination of Indapamide Matrix Tablet: A Thiazide Type Antihypertensive Drug

Por Tazri, Jannatun, Moghal, Md. Mizanur Rahman, Dewan, Syed Masudur Rahman, Noor, Wahiduzzaman, Mohammad, Nor
Publicado em 2014

Validation of the Wild-type Influenza A Human Challenge Model H1N1pdMIST: An A(H1N1)pdm09 Dose-Finding Investigational New Drug Study

Por Memoli, Matthew J., Czajkowski, Lindsay, Reed, Susan, Athota, Rani, Bristol, Tyler, Proudfoot, Kathleen, Fargis, Sarah, Stein, Matthew, Dunfee, Rebecca L., Shaw, Pamela A., Davey, Richard T., Taubenberger, Jeffery K.
Publicado no Clin Infect Dis (2015)

Biochemical criteria of toxicity of therapy with high doses of methotrexate in children with osteosarcoma

Por A. M. Strizhevskaya, E. G. Golovnya, A. Z. Dzampaev, V. N. Baykova
Publicado em 2015-06-01

Tuberculosis drugs’ distribution and emergence of resistance in patient’s lung lesions: A mechanistic model and tool for regimen and dose optimization

Por Strydom, Natasha, Gupta, Sneha V., Fox, William S., Via, Laura E., Bang, Hyeeun, Lee, Myungsun, Eum, Seokyong, Shim, TaeSun, Barry, Clifton E., Zimmerman, Matthew, Dartois, Véronique, Savic, Radojka M.
Publicado no PLoS Med (2019)